Guillain-Barre syndrome: Guillain-BarrC) syndrome (GBS) is the term used to describe a spectrum of rare post-infectious neuropathies that usually occur in otherwise healthy patients. GBS is clinically heterogeneous and encompasses acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS; see these terms) and some other regional variants.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
573 |
4. Check minimum number of eventsNone |
573 |
5. Include endpointsNone |
573 |
6. Filter based on genotype QC (FinnGen only) |
573 |
Control definitions (FinnGen only)
- Control exclude
- G6_POLYNEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- G61
- Name in latin
- Syndroma Guillain-Barré
Similar endpoints
↥List of similar endpoints to
Guillain-Barre syndrome
based on the number of shared cases.
Similar with more cases:
- Polyneuropathies and other disorders of the peripheral nervous system
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4635 | 2063 | 2535 |
| Only index persons | 3894 | 1777 | 2117 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.06 | 0.07 |
| Only index persons | 0.07 | 0.07 | 0.08 |
| Median age at first event (years) | |||
| Whole population | 50.92 | 49.00 | 52.39 |
| Only index persons | 48.14 | 46.19 | 49.78 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 573 | 265 | 308 |
| Unadjusted period prevalence (%) | 0.11 | 0.09 | 0.14 |
| Median age at first event (years) | 52.11 | 48.41 | 55.29 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 510
- Matched controls
- 5102
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G61.0
ICD-10 Finland
Guillain-Barré syndrome
+∞
323.0
425
*
TAB00
NOMESCO Finland
Lumbar puncture
15.2
69.4
120
101
G62.9
ICD-10 Finland
Polyneuropathy, unspecified
62.0
68.3
79
15
G61.9
ICD-10 Finland
Inflammatory polyneuropathy, unspecified
+∞
55.2
52
*
35401
ICD-8 Finland
Polyneuritis and polyradiculitis, Polyradicultitis Guillain-Barré
+∞
53.0
50
*
3570A
ICD-9 Finland
Inflammatory and toxic neuropathy, Acute infective polyneuritis
+∞
48.7
46
*
G61.8
ICD-10 Finland
Other inflammatory polyneuropathies
+∞
45.5
43
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
23.5
37.0
53
25
6BA02
NOMESCO Finland
NA
82.1
34.3
38
5
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.8
32.5
99
202
N03AX12
ATC
gabapentin; oral
4.1
28.5
127
384
WW400
NOMESCO Finland
Plasmaferesis
285.3
27.0
27
*
R20.2
ICD-10 Finland
Paraesthesia of skin
5.6
25.2
78
160
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
27.9
25.2
34
13
ZX120
NOMESCO Finland
Intravenous
4.2
22.3
91
249
G62.8
ICD-10 Finland
Other specified polyneuropathies
+∞
22.0
21
*
N99
ICPC
Neurological disease other
27.8
21.6
29
11
R4120
NOMESCO Finland
Occupational therapy
5.5
20.8
64
130
N03AX16
ATC
pregabalin; oral
2.8
20.3
157
695
N28
ICPC
Limited function/disability (N)
13.9
17.2
29
22
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
3.9
17.0
74
213
G82.2
ICD-10 Finland
Paraplegia, unspecified
31.2
16.2
21
7
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
4.5
14.9
54
131
N29
ICPC
Neurological sympt/complt other
9.0
14.4
30
35
AA1AD
NOMESCO Finland
CT of head and brain
2.4
14.1
148
753
N94
ICPC
Peripheral neuritis/neuropathy
+∞
13.6
13
*
G35
ICD-10 Finland
Multiple sclerosis
12.6
13.2
23
19
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
13.0
101
435
XF400
NOMESCO Finland
ECG with 12 standard connections
2.6
13.0
103
447
R26.8
ICD-10 Finland
Other and unspecified abnormalities of gait and mobility
9.6
12.1
24
26
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
8.7
11.9
25
30
R1250
NOMESCO Finland
Evaluation of functional capability
8.1
11.0
24
31
G51.0
ICD-10 Finland
Bell palsy
6.1
10.9
29
50
N18
ICPC
Paralysis/weakness
8.1
9.7
21
27
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.9
9.7
59
218
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
5.9
9.6
26
46
L28
ICPC
Limited function/disability (L)
2.4
9.6
89
419
R4110
NOMESCO Finland
Physiotherapy
2.0
9.1
140
818
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
4.9
8.7
27
57
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.2
8.6
44
145
H02AB06
ATC
prednisolone; systemic
1.8
8.6
237
1685
N06AA09
ATC
amitriptyline; systemic
2.8
8.5
56
217
N06AX21
ATC
duloxetine; oral
2.6
8.4
60
246
TPH04
NOMESCO Finland
Cathetrisation of vein
2.0
8.2
115
648
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.7
8.0
217
1524
GBB00
NOMESCO Finland
Tracheostomy
9.6
7.8
15
16
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
45.7
7.7
9
*
2AB04
NOMESCO Finland
NA
45.7
7.7
9
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.2
7.7
85
432
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.2
7.7
78
381
H02AB07
ATC
prednisone; oral
2.2
7.5
77
377
G60.0
ICD-10 Finland
Hereditary motor and sensory neuropathy
81.2
7.4
8
*
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
13.6
7.4
12
9
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
13.6
7.4
12
9
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.5
7.4
57
243
L04AX01
ATC
azathioprine; systemic
3.6
7.4
32
94
G63.2*E10.4
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic polyneuropathy
+∞
7.3
7
*
M48.0
ICD-10 Finland
Spinal stenosis
2.3
7.2
64
294
XA402
NOMESCO Finland
ENMG
5.2
7.2
21
42
109
Kela drug reimbursment
Multiple sclerosis
9.0
7.1
14
16
SPAT1215
SPAT
Assessment of need for medical rehabilitation
3.4
7.0
33
103
G04.9
ICD-10 Finland
Encephalitis, myelitis and encephalomyelitis, unspecified
14.0
6.9
11
8
A28
ICPC
Limited function/disability NOS
2.2
6.9
73
364
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
11.1
6.8
12
11
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
9.5
6.8
13
14
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.5
6.8
50
209
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
5.3
6.7
19
37
R53
ICD-10 Finland
Malaise and fatigue
1.9
6.5
99
572
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.7
6.5
43
170
M47.1
ICD-10 Finland
Other spondylosis with myelopathy
9.4
6.3
12
13
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
9.4
6.3
12
13
G61
ICD-10 Finland
Inflammatory polyneuropathy
+∞
6.3
6
*
NA7DM
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with 3 Tesla magnet
+∞
6.3
6
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
2.9
6.1
35
125
N03AE01
ATC
clonazepam; systemic
3.0
6.1
32
110
C03CA01
ATC
furosemide; systemic
1.7
6.1
135
878
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.7
6.0
139
913
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
129
95
17.23
143.72
1.3
1.2
3.9
3.7
mmol/l
0.47
124
87
87
44
23.13
115.42
1.2
1.0
—
—
—
0
0
112
99
13.82
111.26
1.4
1.2
10.0
9.8
e6/l
0.01
92
78
112
99
13.82
111.26
1.5
1.3
492.0
1203.5
e6/l
0.28
93
82
87
50
20.34
108.93
1.2
1.1
—
—
—
0
0
86
50
20.06
107.06
1.2
1.1
—
—
—
0
0
70
36
22.01
91.76
1.3
1.1
75.5
41.7
mg/l
1.70
62
30
62
32
21.60
80.95
1.2
1.0
—
—
—
0
0
53
37
15.68
59.48
1.1
1.4
—
—
—
0
0
44
21
22.61
59.03
1.2
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
46
27
18.44
56.30
1.2
1.1
—
—
—
0
0
45
26
18.70
55.47
1.1
1.0
1.0
1.2
u/l
0.50
25
13
35
15
24.79
48.80
1.3
1.4
—
—
—
0
0
127
360
4.25
40.76
2.6
2.3
10.4
10.6
g/l
0.20
115
332
29
18
16.92
34.25
1.3
1.3
—
—
—
0
0
33
28
12.44
32.78
1.1
1.1
—
—
—
0
0
110
358
3.57
28.34
2.5
2.9
67.2
66.8
g/l
0.18
101
328
255
1330
2.65
28.15
2.7
2.1
841.4
303.4
u/l
0.44
241
1250
24
15
16.66
28.14
1.1
1.1
—
—
—
0
0
24
15
16.66
28.14
1.1
1.2
—
—
—
0
0
24
15
16.66
28.14
1.1
1.1
—
—
—
0
0
23
14
17.07
27.30
1.1
1.1
—
—
—
0
0
40
59
7.21
26.22
1.3
1.1
—
—
—
0
0
22
14
16.30
25.51
1.1
1.0
—
—
—
0
0
22
17
13.42
22.96
1.1
1.1
—
—
—
0
0
51
113
4.86
21.93
1.1
1.1
—
—
—
0
0
15
11
13.98
15.97
1.1
1.1
—
—
—
0
0
143
716
2.33
15.71
3.9
3.4
0.8
0.8
mmol/l
0.57
136
681
52
151
3.69
15.62
2.4
2.5
3.0
3.2
g/l
0.86
42
120
51
147
3.71
15.49
1.8
2.6
10.4
10.6
g/l
0.05
43
127
53
160
3.55
15.03
2.4
2.5
3.4
3.8
g/l
1.80
41
118
53
160
3.55
15.03
2.4
2.5
—
—
—
0
0
53
160
3.55
15.03
2.4
2.5
7.4
7.4
g/l
0.10
41
123
60
199
3.25
14.68
1.9
2.1
32.4
39.2
u/l
1.66
55
178
19
24
8.15
14.09
2.8
2.1
9.7
12.8
%
—
9
11
45
133
3.59
13.16
1.9
2.6
38.3
37.4
g/l
0.37
40
115
360
2666
1.94
12.87
12.0
9.2
4.1
4.1
e9/l
0.04
323
2338
17
21
8.31
12.81
1.1
1.0
—
—
—
0
0
17
21
8.31
12.81
3.0
2.1
—
—
—
0
0
16
5
32.85
12.63
1.3
1.2
—
—
—
0
0
360
2682
1.92
12.46
7.1
4.7
6.7
6.7
mmol/l
0.13
345
2506
46
146
3.34
12.06
2.0
2.8
0.3
1.0
g/l
1.13
41
130
15
5
30.74
11.69
1.1
1.6
—
—
—
0
0
141
781
2.07
11.68
1.8
1.7
1127.6
1164.1
nmol/l
0.19
113
604
110
580
2.11
10.28
7.7
5.8
1.0
1.0
mmol/l
0.10
103
538
36
109
3.46
10.16
1.2
1.3
—
—
—
0
0
272
1939
1.77
10.02
6.4
4.8
34.3
35.7
g/l
3.16
255
1811
23
51
4.66
9.85
1.2
1.8
—
—
—
0
0
252
1771
1.75
9.65
2.3
1.9
91.7
95.1
pmol/l
0.47
150
939
82
394
2.26
9.64
7.4
6.9
9.6
9.7
mmol/l
0.04
77
376
299
2206
1.74
9.63
9.4
6.7
1.2
1.2
mmol/l
0.08
253
1871
14
8
17.90
9.44
1.2
1.4
—
—
—
0
0
277
2018
1.72
9.19
9.0
5.9
1.2
1.2
mmol/l
0.39
254
1836
376
2986
1.75
9.07
6.2
4.3
73.2
1890.8
e6/l
—
10
51
31
94
3.43
8.74
6.3
6.7
1699.1
209.6
iu/ml
—
8
14
158
994
1.81
8.66
2.1
1.7
1.6
1.2
mg/l
0.56
128
764
163
1054
1.76
8.07
1.7
1.5
20.2
20.8
nmol/l
0.20
139
901
233
1666
1.67
7.96
5.0
3.2
—
—
—
0
0
11
6
18.65
7.62
1.2
1.2
—
—
—
0
0
165
1086
1.73
7.61
2.3
2.1
3.1
3.1
mg/l
0.03
128
927
24
68
3.64
7.49
2.6
4.0
—
3459.6
—
0
8
41
164
2.62
7.18
1.3
1.3
5.1
2.3
u/ml
—
5
12
241
1774
1.62
7.14
2.6
2.3
76.5
76.3
nmol/l
0.03
219
1592
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
37
141
2.74
7.11
2.7
2.4
0.3
0.3
u/ml
0.44
18
70
77
406
2.04
7.10
2.5
2.0
323.7
378.7
nmol/l
2.03
69
376
11
17
6.58
6.80
1.1
1.0
1465.1
1433.5
miu/ml
0.03
11
17
45
200
2.36
6.33
1.6
2.2
1.6
1.5
g/l
0.24
40
174
401
3398
1.60
6.10
5.0
4.0
13.8
11.8
mm/h
1.83
373
3132
25
84
3.07
6.03
1.3
1.3
44.9
33.0
u/ml
—
5
9
179
1268
1.60
6.00
4.8
3.0
0.3
0.6
e6/l
1.04
145
946
303
2431
1.52
5.73
6.8
6.4
11.1
11.8
umol/l
0.63
293
2328
17
47
3.70
5.52
1.3
1.9
—
—
—
0
0
72
409
1.87
5.34
4.9
3.6
1.7
1.9
mmol/l
0.21
61
325
249
1941
1.50
5.26
3.0
2.7
283.9
134.7
ug/l
0.68
224
1802
35
153
2.37
5.14
1.2
1.4
—
—
—
0
0
22
78
2.89
4.87
1.3
1.2
—
—
—
0
0
22
78
2.89
4.87
1.3
1.2
—
—
—
0
0
12
28
4.36
4.84
1.3
1.3
—
—
—
0
0
407
3541
1.52
4.79
9.5
7.7
77.6
78.6
u/l
0.15
386
3339
32
139
2.38
4.77
1.5
1.8
—
—
—
0
0
23
87
2.71
4.54
1.1
1.1
—
—
—
0
0
8
8
10.12
4.53
3.3
1.9
—
—
—
0
0
59
332
1.87
4.52
1.9
1.7
—
—
—
0
0
52
281
1.94
4.49
5.2
3.8
2.3
1.7
mmol/l
0.72
41
208
111
751
1.59
4.38
2.3
1.8
—
—
—
0
0
8
9
8.99
4.29
1.0
1.0
—
—
—
0
0
111
764
1.56
4.06
1.3
1.3
37.7
37.9
iu/ml
0.00
25
241
112
774
1.56
4.02
4.0
2.8
1.1
0.9
e6/l
0.28
70
440
150
1112
1.47
3.85
3.2
2.4
—
—
—
0
0
82
533
1.63
3.80
11.5
7.5
1.8
1.0
mmol/l
1.08
67
423
42
225
1.94
3.75
12.8
10.7
24.9
24.4
mmol/l
0.54
37
214
80
519
1.63
3.74
2.3
1.8
—
—
—
0
0
26
116
2.30
3.70
1.5
1.6
—
—
—
0
0
29
136
2.19
3.67
1.3
1.1
—
—
—
0
0
29
136
2.19
3.67
2.8
4.5
32.4
34.9
mg/l
0.14
23
114
29
136
2.19
3.67
2.8
4.5
36.1
105.8
mg/l
0.87
23
112
7
9
7.86
3.56
1.0
1.0
—
—
—
0
0
14
46
3.09
3.55
1.1
1.3
—
—
—
0
0
13
41
3.22
3.51
1.2
1.4
—
—
—
0
0
80
531
1.59
3.41
11.8
7.5
5.2
5.1
kpa
0.56
75
510
80
532
1.59
3.38
11.8
7.5
11.4
12.1
kpa
0.85
74
514
126
925
1.46
3.37
1.9
1.7
446.2
428.8
pmol/l
0.25
105
791
34
176
1.99
3.36
1.8
1.7
—
—
—
0
0
68
436
1.63
3.34
1.7
2.2
0.2
0.2
g/l
0.03
60
412
133
989
1.45
3.32
1.3
1.2
0.6
2.0
u/ml
2.29
29
275
21
90
2.38
3.28
1.4
1.5
—
—
—
0
0
12
38
3.20
3.23
2.0
3.4
—
—
—
0
0
78
524
1.57
3.16
2.2
1.8
—
—
—
0
0
63
403
1.63
3.13
2.7
2.2
12.3
13.6
nmol/l
0.63
57
365
11
34
3.28
3.07
1.1
1.1
—
—
—
0
0
100
714
1.49
3.06
2.5
2.3
12.2
13.2
umol/l
0.71
93
659
27
133
2.08
3.06
1.4
1.2
—
—
—
0
0
264
2227
1.34
3.05
4.7
3.5
0.0
0.0
estimate
0.00
51
431
25
121
2.11
2.97
1.5
1.6
—
—
—
0
0
24
115
2.13
2.92
1.6
1.7
—
—
—
0
0
185
1486
1.36
2.92
3.2
3.4
2.3
2.3
mmol/l
1.20
162
1306
92
654
1.48
2.88
2.3
2.3
2.3
2.3
g/l
0.08
86
607
381
3412
1.35
2.85
3.9
3.8
14.7
14.7
pmol/l
0.21
342
3096
18
77
2.38
2.84
1.4
1.5
—
—
—
0
0
11
36
3.10
2.82
1.1
1.1
—
—
—
0
0
8
18
4.49
2.80
1.5
1.7
25.9
28.6
umol/l
—
8
18
118
886
1.42
2.77
4.4
3.8
372.5
314.2
ng/l
0.08
91
685
12
42
2.90
2.76
2.5
2.0
1076.4
782.9
e6/l
—
5
20
27
139
1.99
2.75
1.8
1.6
0.3
0.1
iu/ml
—
7
26
68
458
1.55
2.74
4.8
3.1
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
7
14
5.05
2.73
1.0
1.0
127.9
138.8
%
—
7
14
101
741
1.44
2.69
4.3
3.0
4.1
1.8
e6/l
0.81
59
409
65
436
1.55
2.67
3.5
2.5
59.1
33.0
u/l
0.44
59
374
16
67
2.43
2.65
1.4
1.6
—
—
—
0
0
31
170
1.87
2.64
1.2
1.3
38.1
24.4
iu/l
0.78
24
145
350
3114
1.32
2.63
4.0
3.2
54.5
48.9
u/l
0.56
325
2936
17
74
2.34
2.60
1.1
1.1
6.3
18.7
iu/ml
—
8
18
78
552
1.48
2.50
3.3
2.8
11.8
8.6
umol/l
0.29
66
479
211
1765
1.31
2.45
4.7
3.6
30.0
35.6
ng/l
0.49
144
1211
261
2247
1.30
2.44
6.2
4.8
0.0
0.0
estimate
0.00
53
432
15
64
2.38
2.40
1.2
1.6
—
—
—
0
0
81
583
1.45
2.39
1.8
1.8
1.4
1.5
%
0.12
68
517
23
118
1.99
2.38
1.3
1.5
—
—
—
0
0
19
91
2.13
2.35
1.3
1.3
245.3
257.8
u/ml
0.08
13
51
84
614
1.43
2.29
2.4
2.4
22.7
23.4
%
0.17
72
534
262
2274
1.28
2.25
4.8
3.5
0.0
0.0
estimate
0.50
53
417
27
150
1.84
2.24
2.1
1.6
—
—
—
0
0
76
548
1.45
2.23
4.8
4.5
32.3
31.8
%
0.10
51
376
5
9
5.59
2.21
1.0
1.0
—
—
—
0
0
5
9
5.59
2.21
1.0
2.9
—
—
—
0
0
5
9
5.59
2.21
1.0
1.0
88.0
96.4
%
—
5
9
147
1185
1.32
2.19
3.4
2.7
2338.5
7384.8
umol/l
1.31
125
1039
18
87
2.10
2.19
1.8
1.6
91.7
111.7
u/ml
—
7
14
37
230
1.65
2.11
1.6
1.3
—
—
—
0
0
178
1481
1.29
2.10
3.3
2.5
53.0
56.4
u/l
1.07
165
1385
8
25
3.23
2.10
1.4
2.7
2270.0
907.5
u/ml
—
8
25
9
31
2.93
2.08
1.0
1.5
—
—
—
0
0
9
31
2.93
2.08
1.0
1.5
—
—
—
0
0
19
96
2.01
2.07
1.7
1.5
—
—
—
0
0
42
272
1.59
2.04
1.5
1.4
—
—
—
0
0
17
83
2.08
2.03
1.6
1.7
—
—
—
0
0
28
163
1.75
2.02
2.0
2.9
—
—
—
0
0
10
38
2.66
2.02
1.2
1.2
—
—
—
0
0
172
1435
1.28
1.97
4.5
3.2
7.3
7.9
mmol/l
1.24
139
1195
21
113
1.89
1.94
1.9
1.8
7.3
6.8
iu/l
—
7
35
10
39
2.59
1.93
1.2
1.2
—
—
—
0
0
249
2178
1.25
1.92
5.0
4.0
—
—
—
0
0
185
1564
1.27
1.90
3.6
3.2
30.3
32.5
u/l
0.73
173
1494
487
4620
1.36
1.89
23.6
13.9
22.1
23.4
mg/l
0.38
414
3691
444
4163
1.30
1.83
4.8
4.5
1.8
2.2
mu/l
0.69
406
3810
5
12
4.19
1.82
1.8
1.1
0.9
2.5
mmol/l
—
5
12
9
35
2.60
1.80
1.0
1.4
—
—
—
0
0
23
131
1.79
1.80
1.4
1.3
—
—
—
0
0
157
1309
1.27
1.80
3.2
3.1
1719.7
1335.0
ng/l
0.33
136
1127
167
1405
1.27
1.77
5.1
4.0
4.1
8.6
mg/mmol
2.50
111
897
15
75
2.03
1.71
1.3
1.1
—
—
—
0
0
18
98
1.86
1.63
1.3
1.3
—
—
—
0
0
495
4736
1.33
1.57
26.5
16.1
4.0
4.0
mmol/l
0.48
484
4606
20
115
1.77
1.54
1.6
1.2
—
—
—
0
0
11
51
2.18
1.51
1.7
1.6
—
—
—
0
0
11
51
2.18
1.51
1.1
1.4
44.6
63.5
%
0.82
11
44
493
4720
1.32
1.51
26.0
16.0
139.5
139.7
mmol/l
1.08
485
4597
13
65
2.02
1.49
1.7
1.5
—
—
—
0
0
16
87
1.86
1.47
2.3
2.1
15.3
16.6
%
—
9
42
9
38
2.39
1.46
1.2
1.2
—
—
—
0
0
7
28
2.52
1.45
1.4
1.7
—
—
—
0
0
9
39
2.33
1.43
1.2
1.2
—
—
—
0
0
9
39
2.33
1.43
1.2
1.2
—
—
—
0
0
41
290
1.45
1.39
1.2
1.2
147.6
149.9
iu/ml
0.01
21
118
39
274
1.45
1.37
1.9
1.7
—
—
—
0
0
6
23
2.63
1.37
1.5
1.7
—
—
—
0
0
5
17
2.96
1.36
6.8
3.2
200.6
209.6
u/l
—
5
17
6
24
2.52
1.30
1.5
1.7
—
—
—
0
0
28
188
1.51
1.23
1.9
1.9
—
—
—
0
0
6
26
2.32
1.19
1.0
1.0
—
—
—
0
0
12
64
1.89
1.18
1.0
1.1
—
—
—
0
0
11
57
1.95
1.17
1.4
1.4
0.6
0.5
nmol/l
0.16
11
52
11
57
1.95
1.17
1.9
1.8
31.3
16.7
ug/l
0.43
11
57
455
4355
1.22
1.12
20.1
12.8
84.1
82.2
ml/min/173m2
1.02
392
3599
18
112
1.63
1.10
1.8
1.8
—
—
—
0
0
5
21
2.39
1.09
3.2
1.9
—
—
—
0
0
142
1236
1.20
1.07
5.8
3.7
0.0
0.0
estimate
0.69
50
420
7
34
2.07
1.03
1.4
1.6
—
—
—
0
0
9
47
1.93
1.02
1.3
1.3
—
—
—
0
0
18
115
1.58
1.00
3.4
1.6
—
—
—
0
0
67
543
1.26
0.99
7.9
7.1
—
—
—
0
0
9
49
1.85
0.99
1.3
1.7
—
—
—
0
0
9
49
1.85
0.99
1.3
1.7
—
—
—
0
0
9
49
1.85
0.99
1.3
1.7
—
—
—
0
0
5
23
2.18
0.98
1.4
1.7
—
—
—
0
0
199
1797
1.16
0.97
5.4
4.9
2.2
3.0
ug/l
0.60
179
1619
14
85
1.66
0.95
2.3
1.6
—
—
—
0
0
6
28
2.15
0.91
1.0
4.0
65.8
87.1
nmol/l
—
6
28
14
86
1.64
0.91
1.5
1.4
—
—
—
0
0
314
2941
1.15
0.91
3.0
3.1
—
—
—
0
0
12
71
1.70
0.89
1.3
1.6
—
—
—
0
0
89
756
1.21
0.88
1.2
1.3
8.1
11.6
u/ml
0.38
29
296
8
43
1.87
0.87
1.1
1.4
—
—
—
0
0
8
44
1.83
0.86
1.3
1.5
—
—
—
0
0
8
44
1.83
0.86
1.5
1.2
0.9
1.5
nmol/l
—
8
39
12
72
1.68
0.85
1.3
1.6
—
—
—
0
0
12
72
1.68
0.85
1.3
1.6
—
—
—
0
0
12
72
1.68
0.85
1.3
1.6
—
—
—
0
0
12
72
1.68
0.85
1.3
1.6
—
—
—
0
0
13
80
1.64
0.85
5.6
3.2
4.3
4.4
e9/l
0.08
13
80
12
73
1.66
0.82
1.3
1.6
—
—
—
0
0
15
99
1.53
0.76
5.5
3.8
31.3
24.1
mg/l
—
8
65
13
83
1.58
0.75
6.4
3.7
58.9
56.9
%
0.20
13
83
5
24
2.09
0.74
1.6
1.5
1.4
1.0
g/l
—
5
24
5
25
2.01
0.73
1.0
3.3
—
—
—
0
0
5
26
1.93
0.70
1.8
1.8
—
—
—
0
0
5
26
1.93
0.70
1.0
1.5
—
—
—
0
0
5
26
1.93
0.70
1.0
1.5
—
—
—
0
0
5
26
1.93
0.70
1.8
1.8
—
—
—
0
0
191
1755
1.13
0.70
5.6
3.6
—
—
—
0
0
7
42
1.67
0.68
1.1
1.0
—
—
—
0
0
28
214
1.32
0.68
3.7
2.3
0.7
0.6
%
0.02
28
208
5
28
1.79
0.66
1.0
1.5
3.4
2.3
u/field
—
5
21
113
1008
1.15
0.65
5.5
3.8
1.0
1.0
kg/l
0.41
18
145
16
112
1.44
0.64
3.3
2.7
8.6
8.3
kpa
0.34
16
100
5
29
1.73
0.64
1.0
1.8
—
—
—
0
0
5
29
1.73
0.64
1.0
1.8
—
—
—
0
0
5
29
1.73
0.64
1.0
1.8
—
—
—
0
0
157
1438
1.13
0.61
4.2
4.3
21.1
21.3
%
0.06
74
685
69
598
1.17
0.58
1.8
1.4
—
—
—
0
0
40
481
0.82
0.56
2.4
4.4
84.0
30.3
ug/l
0.35
26
409
6
39
1.54
0.53
1.2
1.1
—
—
—
0
0
16
117
1.38
0.52
1.1
1.4
—
—
—
0
0
6
40
1.51
0.51
1.2
1.1
—
—
—
0
0
17
127
1.35
0.50
4.5
3.6
1.6
1.5
mg/l
0.10
17
117
426
4370
0.90
0.48
4.3
3.9
1.4
1.3
mmol/l
2.81
379
4047
5
33
1.52
0.41
2.2
3.1
14.4
64.5
u/ml
—
5
33
15
114
1.32
0.41
1.3
1.4
—
—
—
0
0
15
114
1.32
0.41
1.3
1.4
—
—
—
0
0
17
132
1.30
0.40
1.6
2.3
5941.5
3259.5
u/l
—
6
50
8
60
1.34
0.40
1.6
1.5
—
—
—
0
0
15
115
1.31
0.39
1.4
1.4
—
—
—
0
0
15
115
1.31
0.39
1.3
1.4
—
—
—
0
0
9
68
1.33
0.37
1.1
1.3
—
—
—
0
0
8
113
0.70
0.37
1.5
1.2
—
—
—
0
0
113
1048
1.10
0.36
3.4
2.9
0.7
0.8
ug/l
0.31
76
684
457
4651
0.91
0.35
5.0
4.8
2.7
2.7
mmol/l
0.36
407
4306
17
135
1.27
0.35
1.8
1.4
363.1
276.9
miu/ml
—
7
64
6
88
0.68
0.33
1.7
1.5
—
—
—
0
0
447
4549
0.92
0.33
4.7
4.3
1.4
1.4
mmol/l
2.11
398
4219
55
494
1.13
0.32
2.1
2.0
—
—
—
0
0
6
47
1.28
0.32
1.2
1.1
—
—
—
0
0
432
4240
1.08
0.30
6.6
5.6
40.9
39.8
mmol/mol
1.17
390
3955
499
4926
1.10
0.30
14.6
10.3
29.0
27.3
u/l
0.95
482
4772
7
57
1.23
0.29
1.3
3.5
3.0
3.7
nmol/l
—
7
57
15
121
1.25
0.28
1.5
1.5
—
—
—
0
0
60
547
1.11
0.28
2.4
2.2
—
—
—
0
0
8
65
1.23
0.27
1.0
1.1
—
—
—
0
0
450
4567
0.93
0.26
4.6
4.4
4.6
4.6
mmol/l
0.28
404
4261
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
5
43
1.16
0.21
1.0
1.3
1.9
3.2
ug/l
—
5
37
6
53
1.13
0.18
3.0
3.8
—
—
—
0
0
7
62
1.13
0.17
1.3
1.1
—
—
—
0
0
7
63
1.11
0.17
8.0
4.9
385.6
366.1
umol/l
—
7
55
123
1265
0.96
0.11
1.7
1.7
1.4
1.4
mmol/l
0.09
95
1062
61
583
1.05
0.11
23.6
24.4
1.3
1.3
inr
—
8
78
24
222
1.08
0.10
2.2
2.0
—
—
—
0
0
84
812
1.04
0.10
2.7
2.9
2.5
2.4
mmol/l
0.37
77
710
18
164
1.10
0.10
2.6
1.8
—
—
—
0
0
40
421
0.95
0.09
1.7
1.7
—
—
—
0
0
15
136
1.11
0.08
1.4
1.4
—
—
—
0
0
13
117
1.11
0.08
1.8
1.5
—
—
—
0
0
7
64
1.09
0.08
1.0
1.1
2.1
1.5
g/l
—
7
59
38
362
1.05
0.08
3.1
2.8
64.7
68.3
ml/min/173m2
0.25
17
157
20
186
1.08
0.07
1.3
1.9
2.8
2.6
mg/l
0.10
15
134
518
5166
1.03
0.04
33.2
20.6
134.1
136.5
g/l
2.69
509
5094
444
4456
0.98
0.04
5.0
4.4
6.1
5.9
mmol/l
0.75
392
4092
20
192
1.04
0.02
1.8
3.1
9.8
981.9
u/ml
0.74
14
165
22
228
0.96
0.02
1.0
1.0
—
—
—
0
0
388
3890
0.99
0.01
27.8
16.9
13.8
13.7
%
0.81
382
3828
28
273
1.03
0.01
2.2
2.1
—
—
—
0
0
79
797
0.99
0.01
1.7
1.5
—
—
—
0
0
20
195
1.03
0.00
11.7
5.2
1.5
1.6
%
0.20
20
183
20
195
1.03
0.00
1.6
1.5
—
—
—
0
0
13
132
0.98
0.00
1.4
1.4
—
—
—
0
0
425
4251
1.00
0.00
24.6
14.8
39.3
40.1
%
1.02
292
3118
8
89
0.90
0.00
1.5
1.2
10.5
34.5
u/l
—
8
77
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
6
66
0.91
0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
7
73
0.96
0.00
2.0
1.6
—
—
—
0
0
0
9
0.00
0.00
0.0
3.1
—
82.8
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_GUILBAR and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_GUILBAR | 2.186 [1.81, 2.63] | < 0.001 |
| Birth year | 0.997 [0.99, 1.01] | 0.473 |
During the follow-up period (1.1.1998 — 31.12.2019), 256 out of 1332 females with G6_GUILBAR died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_GUILBAR | 1.876 [1.59, 2.21] | < 0.001 |
| Birth year | 0.983 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 391 out of 1622 males with G6_GUILBAR died.
Mortality risk
Mortality risk for people of age
years, who have G6_GUILBAR.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.24% | 0.382% |
| 5 | 1.313% | 1.977% |
| 10 | 3.35% | 4.535% |
| 15 | 6.366% | 8.683% |
| 20 | 11.367% | 14.611% |
Relationships between endpoints
↥Index endpoint: G6_GUILBAR – Guillain-Barre syndrome
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data